Cardiometabolic Modulation by Semaglutide Contributes to Cardioprotection in Rats with Myocardial Infarction
Haihao Yan,Wenjing Yao,Yanhong Li,Tianxing Li,Kexin Song,Pan Yan,Yi Dang
DOI: https://doi.org/10.2147/dddt.s491970
IF: 4.3188
2024-11-30
Drug Design Development and Therapy
Abstract:Haihao Yan, 1, 2 Wenjing Yao, 2 Yanhong Li, 1 Tianxing Li, 3 Kexin Song, 1 Pan Yan, 4 Yi Dang 2 1 Department of Internal Medicine, Graduate School of Hebei Medical University, Shijiazhuang, Hebei, 050017, People's Republic of China; 2 Department of Cardiology Center, Hebei General Hospital, Shijiazhuang, Hebei, 050051, People's Republic of China; 3 Department of Graduate School of Hebei North University, Zhangjiakou, Hebei, 075000, People's Republic of China; 4 Department of Internal Medicine, Yongnian District Traditional Chinese Medicine Hospital, Handan, Hebei, 057150, People's Republic of China Correspondence: Yi Dang, Department of Cardiology Center, Hebei General Hospital, Shijiazhuang, Hebei, People's Republic of China, Tel +86-0311-85988645, Email Background: Acute myocardial infarction (AMI) is a significant clinical challenge. Semaglutide has therapeutic potential in cardiovascular disease management, but its specific impact and mechanisms in AMI are not fully understood. Methods: Twenty-four male Sprague-Dawley rats were divided into three groups: control (Control), infarction-only (MI), and semaglutide-treated (SEMA). Weight, blood glucose, and lipid profiles were analyzed. Cardiac function was evaluated via echocardiography. Histopathological assessment and immunohistochemical analysis were performed. Untargeted metabolomic analysis using LC-MS/MS was utilized. Results: Semaglutide treatment was associated with a reduction in body weight, blood glucose, total cholesterol (TC), and low-density lipoprotein cholesterol (LDL-C), as well as an enhancement in the left ventricular ejection fraction (Control vs MI vs SEMA, 69.13± 4.30 vs 30.16± 3.17 vs 39.81± 6.13, P < 0.05). It also had a lower collagen volume fraction (3.05 vs 34.05 vs 17.73, P < 0.05) and ameliorated the accumulation of glycogen in the myocardium. Metabolomic profiling revealed differentially expressed metabolites between the control/MI and MI/SEMA groups, predominantly within benzenoid, lipid, and organic acid categories. Pathway enrichment analysis highlighted amino sugar and nucleotide sugar metabolism, chlorocyclohexane and chlorobenzene degradation, and phenylalanine, tyrosine, and tryptophan biosynthesis. Random forest analysis identified key metabolites, including downregulated Docusate sodium, 1-(2-Thienyl)-1-heptanone, and Adenylyl-molybdopterin, alongside upregulated Methylenediphosphonic acid, Choline sulfate, and Lactosamine. Conclusion: Semaglutide significantly ameliorated myocardial fibrosis and metabolic dysregulation in rats post-myocardial infarction. Its mechanism involves modulating glucose metabolism, lipid metabolism, and organic acid metabolism. Targeted metabolites, including Docusate sodium, 1-(2-Thienyl)-1-heptanone, Adenylyl-molybdopterin, Methylenediphosphonic acid, Choline sulfate, and Lactosamine, are implicated in the metabolic reprogramming induced by semaglutide. Keywords: semaglutide, myocardial infarction, cardiometabolic, untargeted metabolomic analysis, glucagon-like peptide-1 receptor agonists Acute myocardial infarction (AMI) is a common clinical emergency with significant pathophysiological processes involving myocardial cell necrosis, inflammatory responses, fibrosis, and cardiac energy metabolic disorders. 1,2 Heart failure induced by myocardial infarction is an important cause of cardiovascular death in patients. 3 Current treatments include β-blockers, angiotensin II receptor blockers, and angiotensin-converting enzyme (ACE) inhibitors, 4 but the incidence of adverse myocardial remodeling and progression to heart failure after myocardial infarction remains high. Therefore, there is an urgent need to develop new drugs to delay cardiac remodeling after myocardial infarction. The myocardium is a high-workload, high-energy-consuming tissue that requires an ample energy supply. The normal myocardial energy metabolic pathways are highly adaptable, with 40%–60% of energy derived from fatty acid β-oxidation, and 20%–40% from the oxidation of glucose, lactate, and ketone bodies. After myocardial infarction, the increased energy demand of the heart coupled with a reduced blood supply leads to alterations in cardiac metabolic pathways, promoting cardiac remodeling. 5,6 Current research suggests that normalizing the uptake and oxidation of myocardial glucose and fatty acids by modulating downstream metabolic signals can improve adverse remodeling in the ischemic myocardium. 7,8 Glucagon-like peptide-1 receptor agonists (GLP-1RAs), such as semaglutide, constitute a new class of hypoglycemic drugs that reduce the incidence of cardiovascular adv -Abstract Truncated-
pharmacology & pharmacy,chemistry, medicinal